Nucleus Genomics has announced a new addition to its growing IVF+ Clinic Network, confirming that the Fertility Institute of Hawaii Joins Nucleus IVF+ as its latest clinical partner. The collaboration brings Nucleus' advanced carrier screening and embryo analysis capabilities to Hawaii's largest IVF practice, giving patients on the islands and the many international patients who travel there access to some of the most comprehensive genetic insight currently available in reproductive medicine.

The announcement was made on June 9, 2026, from New York and marks another significant step in Nucleus Genomics' rapid geographic expansion across the United States and the broader Asia-Pacific corridor.

Hawaii's Gateway Position in Pacific Reproductive Care

The Fertility Institute of Hawaii, based in Honolulu and founded by Dr. John Frattarelli, has been delivering fertility care for more than two decades. Over that time, its physicians have helped bring more than 15,000 babies into the world, establishing it as the most comprehensive IVF practice across the Hawaiian Islands. Beyond its local patient base, the clinic serves a substantial number of international patients who travel to Hawaii specifically for fertility treatment, families from Japan, Korea, China, Australia, and New Zealand, for whom the partnership with Nucleus now unlocks a new tier of genetic analysis.

That international dimension is part of what makes the Fertility Institute of Hawaii Joins Nucleus IVF+ announcement particularly strategically significant. Hawaii's geographic position as a crossing point between North America and Asia makes it a natural hub for cross-border reproductive care, and Nucleus' expanding interest in Asia-Pacific markets gives the partnership meaning well beyond the islands themselves.

What Patients Can Now Access

Through the collaboration, patients undergoing IVF at the Fertility Institute of Hawaii will gain significantly deeper genetic insight into their embryos. The assessment covers risk profiles tied to a range of serious conditions, including cancers, heart disease and diabetes that are known to be especially prevalent across Pacific populations.

Nucleus delivers this through two core services: Preview, its advanced carrier screening offering, and Embryo, its detailed embryo analysis platform. Combined, these tools screen for more than 2,000 genetic conditions and traits. Critically, the scope extends well beyond what is typically offered during standard IVF, encompassing conditions such as endometriosis, type 1 diabetes, breast cancer, heart disease, and Alzheimer's disease, none of which are part of conventional IVF screening protocols.

The clinical value of that additional coverage becomes especially clear when Nucleus applies its genetic optimization models to the selection process. When prospective parents are choosing among five embryos, those models have demonstrated average relative risk reductions of 31.9% for endometriosis, 67% for type 1 diabetes, 42% for breast cancer, 35% for heart disease, and 55% for Alzheimer's disease. Those figures represent a meaningful quantitative improvement in the odds a family faces over a lifetime, not merely in the outcome of a single IVF cycle.

The Clinical and Strategic Rationale

Dr. Nathan Treff, Chief Clinical Officer at Nucleus Genomics, articulated the reasoning behind this particular partnership. "When choosing which embryo to transfer, patients want more information during IVF. The Fertility Institute of Hawaii has helped families across Hawaii and the Pacific for decades. We're excited to work alongside a team so deeply trusted by its patients and community."

The sentiment was matched by Dr. John Frattarelli, Founder, CEO, and Medical Director of the Fertility Institute of Hawaii. "The future of IVF is genomic. Our partnership with Nucleus reflects what we've always believed: patients in Hawaii shouldn't have to leave home or settle for less. We're proud to be the first in the state to offer this level of embryo genetic analysis, and even prouder that it enables our local and international patients to make their most consequential decisions with the most complete information available."

That phrase, "the most consequential decisions", points to something important about how the field is shifting. Embryo selection has historically been a clinical judgement call based on morphology and development stage. The arrival of polygenic risk screening and comprehensive genetic optimization models changes the nature of that decision, adding a layer of probabilistic health data that reaches decades into a child's future.

Nucleus Genomics' Rapid Network Growth

The Fertility Institute of Hawaii joining Nucleus IVF+ comes at a moment of considerable momentum for Nucleus Genomics as a company. In recent months, the firm has announced clinic partnerships in California, New York, India, and the Middle East, a geographic spread that reflects both the universality of patient demand for genetic insight in IVF and the company's ambition to become the standard platform for that insight globally.

The Nucleus IVF+ Clinic Network is growing rapidly, and the company currently maintains a waitlist of more than 3,000 patients. That figure alone signals the extent to which demand is outpacing supply and helps explain why partnerships with established, high-volume practices like the Fertility Institute of Hawaii are central to the network's expansion strategy.

Nucleus Genomics, which has raised more than $32 million to date with backing from Founders Fund, Seven Seven Six, Samsung Next, and Quiet Capital, is building toward what it describes as a new standard for how families plan for the next generation. The integration of advanced genomics into routine IVF care, rather than treating genetic analysis as an optional add-on, sits at the core of that vision.